Clinical Trial Update: Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CTX-471 as a monotherapy or in combination with pembrolizumab in patients who progressed after PD-1/PD-L1 inhibitors across metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Malignant Mesothelioma
• Melanoma
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• CTX-471
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Compass Therapeutics | Conditions: Locally Advanced Solid Tumor, Metastatic Cancer | Phase 1 | Status: COMPLETED